CD40 and ovarian cancer: Secondly, evidence has emerged that TAM-mediated immunosuppression underpins the lack of efficacy displayed by ovarian cancer patients in response to ICB, and therefore ICB in combination with anti-CD40 treatment has been advanced as a potentially efficacious strategy (Figure 3) [57].